Montana Restart and New Claims Could Be A Game Changer For United States Antimony (UAMY)

• United States Antimony Corporation recently restarted mining operations at its Montana properties following a winter shutdown, introduced GPS-based vein mapping and mulch-based reclamation practices, and expanded its portfolio with new antimony-focused mining claims in Alaska, Montana, and Ontario.
• These operational changes and resource acquisitions could meaningfully influence how investors assess the company’s production potential, asset base, and long-term operating profile.
• We’ll now examine how the restart of Montana mining operations and expanded North American claims may influence United States Antimony’s investment narrative.

This technology could replace computers: discover 25 stocks that are working to make quantum computing a reality.

United States Antimony Investment Narrative Recap

To be a shareholder in United States Antimony, you need to believe that its vertically integrated antimony platform can convert growing domestic critical mineral attention into durable sales and, eventually, consistent profits. The restart of Montana mining and the new North American claims are relevant for near term volume and supply security, but the more immediate catalyst and risk still sit with permitting progress, cost control and the company’s ability to turn higher throughput into improved margins.

Among recent developments, the February 2026 joint venture with Americas Gold and Silver to build an antimony processing plant in Idaho stands out. It ties directly into the same investment debate as the Montana restart: can US Antimony secure enough feedstock and processing capacity to support higher volumes without stretching its balance sheet and operational capabilities, especially given its history of losses and earnings volatility.

Yet behind the potential upside, investors should also be aware of the risk that concentrated long term contracts and permitting hurdles could...

Read the full narrative on United States Antimony (it's free!)

United States Antimony's narrative projects $327.7 million revenue and $84.7 million earnings by 2029. This requires 102.9% yearly revenue growth and an $89.0 million earnings increase from -$4.3 million today.

Uncover how United States Antimony's forecasts yield a $12.67 fair value, a 46% upside to its current price.

Exploring Other Perspectives

Some analysts were already assuming revenue could reach about US$333 million and earnings about US$72 million by 2029, which is far more optimistic than the baseline view. When you set those expectations alongside the recent Montana restart and the long term contract and permitting risks, it highlights how differently you and other investors might interpret the same news and why it is worth comparing several viewpoints before deciding what this latest update means for you.

Explore 18 other fair value estimates on United States Antimony - why the stock might be worth less than half the current price!

The Verdict Is Yours

Disagree with existing narratives? Extraordinary investment returns rarely come from following the herd, so go with your instincts.

• A great starting point for your United States Antimony research is our analysis highlighting 2 key rewards and 3 important warning signs that could impact your investment decision.
• Our free United States Antimony research report provides a comprehensive fundamental analysis summarized in a single visual - the Snowflake - making it easy to evaluate United States Antimony's overall financial health at a glance.

Want Some Alternatives?

Our daily scans reveal stocks with breakout potential. Don't miss this chance:

• Capitalize on the AI infrastructure supercycle with our selection of the 36 best 'picks and shovels' of the AI gold rush converting record-breaking demand into massive cash flow.
• We've uncovered the 12 dividend fortresses yielding 5%+ that don't just survive market storms, but thrive in them.
• AI is about to change healthcare. These 37 stocks are working on everything from early diagnostics to drug discovery. The best part - they are all under $10b in market cap - there's still time to get in early.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com